Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation

James S. Gammie, Michael W.A. Chu, Volkmar Falk, Jessica R. Overbey, Alan J. Moskowitz, Marc Gillinov, Michael J. Mack, Pierre Voisine, Markus Krane, Babatunde Yerokun, Michael E. Bowdish, Lenard Conradi, Steven F. Bolling, Marissa A. Miller, Wendy C. Taddei-Peters, Neal O. Jeffries, Michael K. Parides, Richard Weisel, Mariell Jessup, Eric A. RoseJohn C. Mullen, Samantha Raymond, Ellen G. Moquete, Karen O’Sullivan, Mary E. Marks, Alexander Iribarne, Friedhelm Beyersdorf, Michael A. Borger, Arnar Geirsson, Emilia Bagiella, Judy Hung, Annetine C. Gelijns, Patrick T. O’Gara, Gorav Ailawadi

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

BACKGROUND Tricuspid regurgitation is common in patients with severe degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform tricuspid-valve repair during mitral-valve surgery in patients who have moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation. METHODS We randomly assigned 401 patients who were undergoing mitral-valve surgery for degenerative mitral regurgitation to receive a procedure with or without tricuspid annuloplasty (TA). The primary 2-year end point was a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation by two grades from baseline or the presence of severe tricuspid regurgitation, or death. RESULTS Patients who underwent mitral-valve surgery plus TA had fewer primary-end-point events than those who underwent mitral-valve surgery alone (3.9% vs. 10.2%) (relative risk, 0.37; 95% confidence interval [CI], 0.16 to 0.86; P=0.02). Two-year mortality was 3.2% in the surgery-plus-TA group and 4.5% in the surgery-alone group (relative risk, 0.69; 95% CI, 0.25 to 1.88). The 2-year prevalence of progression of tricuspid regurgitation was lower in the surgery-plus-TA group than in the surgery-alone group (0.6% vs. 6.1%; relative risk, 0.09; 95% CI, 0.01 to 0.69). The frequencies of major adverse cardiac and cerebrovascular events, functional status, and quality of life were similar in the two groups at 2 years, although the incidence of permanent pacemaker implantation was higher in the surgery-plus-TA group than in the surgery-alone group (14.1% vs. 2.5%; rate ratio, 5.75; 95% CI, 2.27 to 14.60). CONCLUSIONS Among patients undergoing mitral-valve surgery, those who also received TA had a lower incidence of a primary-end-point event than those who underwent mitral-valve surgery alone at 2 years, a reduction that was driven by less frequent progression to severe tricuspid regurgitation. Tricuspid repair resulted in more frequent permanent pacemaker implantation. Whether reduced progression of tricuspid regurgitation results in long-term clinical benefit can be determined only with longer follow-up.

Original languageEnglish (US)
Pages (from-to)327-339
Number of pages13
JournalNew England Journal of Medicine
Volume386
Issue number4
DOIs
StatePublished - Jan 27 2022

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation'. Together they form a unique fingerprint.

Cite this